On June 11, 2021, Janux Therapeutics, Inc., a biopharmaceutical company developing novel T cell engager immunotherapies, announced the pricing of its initial public offering of 11,400,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Janux from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $193.8 million. All of the shares are being offered by Janux. In addition, Janux has granted the underwriters a 30-day option to purchase up to an additional 1,710,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on June 11, 2021, under the ticker symbol "JANX." 

A Wilson Sonsini Goodrich & Rosati team that included Laurie McNamara, Stephanie Dusaban Gonzales, Jennifer Floyd, Uale Taotafa, and Michael Hostetler​ advised Janux Therapeutics on patent matters related to the offering.​

For more information, please see Janux's press release.